<DOC>
	<DOCNO>NCT01344707</DOCNO>
	<brief_summary>The purpose study determine Maximum Tolerated Dose , Dose Limiting Toxicities optimal dose schedule 4SC-202 investigating safety , tolerability pharmacokinetics .</brief_summary>
	<brief_title>Oral Histone Deacetylase Inhibitor 4SC-202 Patients With Advanced Hematologic Malignancies ( TOPAS )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Male female patient , age â‰¥ 18 year . Patients Acute Myeloid Leukemia ( AML ) , Acute Lymphocytic Leukemia ( ALL ) , Chronic Lymphocytic Leukemia ( CLL ) , Multiple Myeloma ( MM ) , Myelodysplastic Syndrome ( MDS ) malignant lymphoma relapse and/or refractory standard therapy standard therapy exists . Patients eligible curative stem cell transplantation patient refuse eligible frontline ( chemo ) therapy may also include . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Patients must live expectancy 12 week . Patients must adequate bone marrow reserve well adequate renal hepatic function serum electrolytes within clinically acceptable range . Patients must recover treatmentrelated toxicity ( Grade 0 1 accord Common Terminology Criteria Adverse Events ( CTCAE ) ; except alopecia , fatigue Grade 1 neurotoxicity ) prior registration . Patients receive previous treatment HDAC inhibitor . Patients gastrointestinal disorder could interfere absorption 4SC202 Patients unable take oral medication . Patients history malignancy unless undergone definitive treatment 5 year prior entry study without evidence recurrent malignant disease , exclude patient basal cell carcinoma skin ; superficial carcinoma bladder ; carcinoma prostate current prostate specific antigen ( PSA ) value &lt; 0.1 ng/ml ; cervical intraepithelial neoplasia . Patients history , treat , suspect , hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . Patients suspect condition undergo appropriate evaluation prior enrol study . Patients precedent anticancer therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within last two week longer period depend know PK characteristic agent use . Patients history current evidence clinically relevant allergy idiosyncrasy drug ( especially similar chemical composition study drug ) food . Patients symptomatic brain metastases/central nervous system ( CNS ) involvement . Patients significant cardiovascular disease include unstable angina pectoris , uncontrolled hypertension , congestive heart failure ( New York Heart Association ( NYHA ) Class III IV ) relate primary cardiac disease , condition require antiarrhythmic therapy , ischemic severe valvular heart disease , myocardial infarction within 6 month prior trial entry . Patients mark baseline prolongation QT/QTc interval , e.g. , repeat demonstration QTc interval &gt; 450 msec ( Grade 1 CTCAE ) ; LongQTSyndrome ; require use concomitant medication 4SC202 dosing day may cause Torsade de Pointes . Therapy agent know prolong QT interval , certain antibiotic ( i.e . erythromycin , clarithromycin ) , antidepressant ( i.e . doxepin , amitryptilin ) neuroleptic ( i.e . haloperidol , clozapin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Acute Myeloid Leukemia ( AML )</keyword>
	<keyword>Acute Lymphocytic Leukemia ( ALL )</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Multiple Myeloma ( MM )</keyword>
	<keyword>Myelodysplastic Syndrome ( MDS )</keyword>
	<keyword>Malignant Lymphomas</keyword>
	<keyword>Histone Deacetylase ( HDAC )</keyword>
	<keyword>4SC-202</keyword>
	<keyword>Phase I</keyword>
</DOC>